Related Experiment Video
Updated: Dec 7, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Identification of genes and miRNAs in paclitaxel treatment for breast cancer
Jie Wu1, Yijian Zhang2,3, Maolan Li2
1Key Laboratory of Hydrodynamics (Ministry of Education), School of Naval Architecture, Ocean and Civil Engineering, Shanghai Jiao Tong University, Shanghai, China.
Aim:
Paclitaxel is a microtubule-stabilizing drug that has therapeutic effect on breast cancer. However, the molecular mechanism of paclitaxel on breast cancer has not been elucidated.
Materials And Methods:
Microarray data of GSE114403, including 50 pretreatment and 50 posttreatment samples, were downloaded from public database. The differentially expressed genes (DEGs) between pretreatment and posttreatment were identified, followed by functional enrichment analysis. Then, protein-protein interaction (PPI) network and transcription factor (TF)-miRNA-mRNA network were constructed. Finally, the survival analysis of hub genes was performed.
Results:
A total of 107 DEGs were screened from pretreatment versus posttreatment. Genes were significantly enriched in GO terms such as inflammatory response, and pathways like cytokine-cytokine receptor interaction pathway. CXCL2, PTGS2, and ATF3 were considered as hub genes in PPI network. TFs such as FOXA2, NFE2L2, as well as miRNAs like has-miR-508-3p and has-miR-584 also played role in the paclitaxel treatment. Additionally, survival analysis revealed that breast cancer patients with high expression level of CXCL2, PTGS2, and ATF3 had longer survival time.
Conclusion:
In summary, we demonstrated that CXCL2, PTGS2, and ATF3 might be diagnostic and therapeutic molecular biomarkers for breast cancer. These findings might provide further insights into the pathophysiology of breast cancer, as well as enhance our understanding of the anticancer effects of paclitaxel.
Insights
Paclitaxel treatment for breast cancer involves key genes CXCL2, PTGS2, and ATF3. High expression of these genes indicates longer survival, suggesting their potential as diagnostic and therapeutic biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Paclitaxel is a microtubule-stabilizing drug used in breast cancer therapy.
- The precise molecular mechanisms underlying paclitaxel's effects on breast cancer remain unclear.
Purpose of the Study:
- To elucidate the molecular mechanisms of paclitaxel in breast cancer.
- To identify potential diagnostic and therapeutic biomarkers for breast cancer patients treated with paclitaxel.
Main Methods:
- Analysis of microarray data (GSE114403) comparing pre- and post-treatment samples.
- Identification of differentially expressed genes (DEGs), functional enrichment analysis, and construction of protein-protein interaction (PPI) and TF-miRNA-mRNA networks.
- Survival analysis of identified hub genes.
Main Results:
- 107 DEGs were identified between pre- and post-treatment samples.
- Enrichment analysis revealed significant involvement in inflammatory response and cytokine-cytokine receptor interaction.
- CXCL2, PTGS2, and ATF3 were identified as hub genes, with higher expression correlating with longer patient survival.
Conclusions:
- CXCL2, PTGS2, and ATF3 show potential as diagnostic and therapeutic molecular biomarkers for breast cancer.
- These findings enhance understanding of breast cancer pathophysiology and paclitaxel's anticancer effects.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:22MicroRNAs
01:22MicroRNAs